|1.||Greish, Khaled: 3 articles (08/2012 - 04/2007)|
|2.||Fang, Jun: 3 articles (08/2012 - 04/2007)|
|3.||Maeda, Hiroshi: 3 articles (08/2012 - 04/2007)|
|4.||Maeda, H: 2 articles (08/2009 - 03/2007)|
|5.||Iyer, Arun K: 2 articles (08/2007 - 04/2007)|
|6.||Takeya, Motohiro: 1 article (08/2012)|
|7.||Nakamura, Hideaki: 1 article (08/2012)|
|8.||Liao, Long: 1 article (08/2012)|
|9.||Qin, Haibo: 1 article (08/2012)|
|10.||Vales, A: 1 article (08/2009)|
|1.||Liver Neoplasms (Liver Cancer)
08/01/2012 - "In vitro experiments using 11 cultured tumor cell lines and six normal cell lines revealed a remarkable cytotoxicity of SMA-ZnPP against various tumor cells; average IC(50) is about 11.1 μM, whereas the IC(50) to various normal cells is significantly higher, that is, more than 50 μM. "
08/01/2009 - "Interestingly, several of the drug partners, when applied as single agents, induced the expression of Hsp32 in neoplastic cells, suggesting that synergistic effects resulted from SMA-ZnPP-induced ablation of a Hsp32-mediated survival-pathway that is otherwise used by tumor cells to escape drug-induced apoptosis. "
08/01/2007 - "The micellar macromolecular drug of ZnPP (SMA-ZnPP and PEG-ZnPP) previously showed notable anticancer activity as a consequence of selective tumor targeting ability and its potent HO-1 inhibitory potential, resulting in suppressed biliverdin/bilirubin production in tumors thereby leading to oxystress induced tumor cell killing. "
|3.||T-Cell Leukemia (Leukemia, T Cell)
|4.||Esophageal Neoplasms (Esophageal Cancer)
04/01/2007 - "The micelles showed a constant ZnPP release rate of about 0.5%/day in vitro at neutral pH. SMA-ZnPP micelles inhibited splenic microsomal HO-1 activity, in a competitive and dose-dependent manner, with an apparent inhibitory constant (K(i)) of 0.12mum, comparable to free ZnPP and also exhibited marked cytotoxic effect on KYSE-510 human esophageal cancer cells. "
|1.||pegylated zinc protoporphyrin